Richard S. Finn

机构：University of California, Los Angeles, The Royal Free Hospital, University College London · ORCID：0000-0003-2494-2126

发表论文 759 篇 · 总被引 83746 次 · h-index 102

代表论文

• The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment (2025 · The Lancet · 被引 164)
• Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study (2025 · Journal of Hepatology · 被引 14)
• Depth and Duration of Response Are Associated with Survival in Patients with Unresectable Hepatocellular Carcinoma: Exploratory Analyses of IMbrave150 (2025 · Liver Cancer · 被引 14)
• Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studies (2025 · JHEP Reports · 被引 10)
• Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapy (2025 · Cell Reports Medicine · 被引 7)
• LEAP-002 long-term follow-up: Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma. (2025 · Journal of Clinical Oncology · 被引 6)